Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2018-01-18
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To describe the global incidence of invasive Candida infection To monitor trends globally and locally over time To define patient risk groups To assess antifungal resistance among Candida spp. causing invasive diseases worldwide To assess attributable mortality of invasive Candida infection To assess incremental costs associated with invasive Candida infection
To describe the clinical pattern of disease To document diagnostic procedures performed for confirmation of diagnosis To describe first-line and salvage treatment regimens applied, guideline adherence, their efficacy and impact on patient survival To inform consensus guidelines To develop clinical screening and diagnostic procedures
Set up of a collection of isolates with molecular characterization and evaluation of resistance genes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
emerging Candida isolates
Web-based registry of invasive infections by Candida species
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hepatosplenic candidiasis with signs of disseminated Candida infection without culture, histological or microscopic evidence
* Case control
Matching procedure for controls:
In part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital).
Controls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Cornely, MD
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Cornely, MD
Role: STUDY_CHAIR
University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Oliver Cornely, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Candi001
Identifier Type: -
Identifier Source: org_study_id